Theranexus   Report issue

For profit Phase 1 Phase 2
Founded: Orsay France (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2015
NCT03182413
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Theranexus

Active Ingredients

Drugs in Phase 2 Trials (2)

miglustat (zavesca) (1 trial)

modafinil (provigil) (3 trials)

Drugs in Phase 1 Trials (2)

donepezil (aricept) (1 trial)

mefloquine (lariam) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Cognitive Dysfunction (Phase 1)

Narcolepsy (Phase 2)

Parkinson Disease (Phase 2)

Sleep Deprivation (Phase 1)

Sleepiness (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 4